Literature DB >> 24167747

Inhibition of Nitric Oxide Synthase by L-NAME Promotes Cisplatin-Induced Nephrotoxicity in Male Rats.

Fatemeh Moslemi1, Mehdi Nematbakhsh, Fatemeh Eshraghi-Jazi, Ardeshir Talebi, Hamid Nasri, Farzaneh Ashrafi, Maryam Moeini, Azam Mansouri, Zahra Pezeshki.   

Abstract

Objective. Nitric oxide (NO) has numerous important functions in the kidney. The role of NO in cisplatin (CP)-induced nephrotoxicity is not completely understood. This study was designed to determine the role of NO synthase inhibitor (L-NAME) on the severity of CP-induced nephrotoxicity in rats. Methods. Sixty four male (M) and female (F) Wistar rats were randomly divided into eight groups. The sham groups (group 1, male, n = 6 and group 2, female, n = 6) received saline. Groups 3 (male, n = 8) and 4 (female, n = 8) were treated with L-NAME (4 mg/kg, i.p.), and groups 5 (male, n = 8) and 6 (female, n = 8) received CP (3 mg/kg) for 7 days. Groups 7 (male, n = 8) and 8 (female, n = 8) were treated with L-NAME and CP for 7 days. Results. The CP-alone treated rats showed weight loss and increase in serum levels of blood urea nitrogen (BUN) and creatinine (Cr). Coadministration of L-NAME and CP did not improve weight loss, and it increased the levels of BUN and Cr in male but not in female rats (P < 0.05). CP alone increased kidney damage significantly (P < 0.05 ), however, the damage induced by combination of CP and L-NAME was gender-related. Conclusion. NOS inhibition by L-NAME increased CP-induced nephrotoxicity, which was gender-related.

Entities:  

Year:  2013        PMID: 24167747      PMCID: PMC3791574          DOI: 10.1155/2013/242345

Source DB:  PubMed          Journal:  ISRN Toxicol        ISSN: 2090-6188


1. Introduction

Cisplatin (CP) is an effective antineoplastic agent against solid tumors in clinic [1]. Despite the antineoplastic efficacy, the optimal clinical usefulness of CP is usually limited due to its side effects such as nephrotoxicity. CP exerts its nephrotoxic effect mainly in the proximal tubular cells where it is preferentially accumulated [2]. The CP-induced nephrotoxicity may be gender related [3], but the mechanism underlying this sex difference is not understood. Studies have shown that female animals are more sensitive to induce acute renal failure (ARF) [4] and CP enhances urinary sodium excretion in male rats but not in females [5]. Different metabolism and sex hormones [6] may involve in CP-induced nephrotoxicity to be sex related. Nitric oxide (NO) has been suggested to play an important role in CP-induced nephrotoxicity [7, 8]. L-arginine, the precursor of NO, attenuates CP-induced nephrotoxicity in male rats, but it intensifies renal damage induced by CP in female rats [9]. In addition, administration of the nonselective inhibitor of NO synthase, N-nitro L-arginine methyl ester hydrochloride (L-NAME), exacerbates CP-induced nephrotoxicity [10]. The present study was carried out to determine whether administration of L-NAME against nephrotoxicity induced by CP differs between male and female in animal model.

2. Methods and Materials

2.1. Animals

Sixty-four adult male and female Wistar rats, weighting 176.23 ± 2.15 and 180.77 ± 2.3 g, respectively, (Animal Center, Isfahan University of Medical Sciences, Isfahan, Iran) were used in this research project. The animals were individually housed at a temperature range of 23–25°C. The rats had free access to water and rat chow. The rats were acclimatized to the diet for at least one week prior to the experiment. The experimental procedures were in advance approved by the Isfahan University of Medical Science Ethics Committee.

2.2. Experimental Protocol

The animals were randomly divided into eight groups and treated for seven consecutive days as follows. The sham groups (group 1, male, n = 6, and group 2, female, n = 6) received saline. Groups 3 (male, n = 8) and 4 (female, n = 8) received L-NAME (4 mg/kg/day, i.p.), groups 5 (male, n = 8) and 6 (female, n = 8) received CP (3 mg/kg/day, i.p.), and groups 7 (male, n = 8) and 8 (female, n = 8) received combination of L-NAME (4 mg/Kg/day, i.p.) and CP (3 mg/Kg/day, i.p.). The body weight of animals was recorded daily. At the end of the experiment on day 8, all animals were anesthetized with ketamine (75 mg/kg). Blood samples were withdrawn by heart puncture, centrifuged at 6000 rpm for 20 min, and the serum was separated. The serum samples were stored at −20°C until measurement. Then, all animals were sacrificed. The kidneys were removed, freed from the surrounding fats, and weighted immediately. For each animal, the left kidney was fixed in 10% formalin for histopathological investigations.

2.3. Measurements

The levels of serum creatinine (Cr) and blood urea nitrogen (BUN) were determined using quantitative diagnostic kits (Pars Azmoon, Tehran, Iran). The serum level of nitrite (NO stable metabolite) was measured by an ELISA kit that involves the Griess reaction. Briefly, after adding sulfanilamide solution and incubation, N-(1-naphthyl) ethylenediamine dihydrochloride solution was added. Then absorbance was measured with a microreader, and the nitrite concentration of samples was determined by comparison with the nitrite standard reference curve.

2.4. Histopathological Procedures

The removed left kidneys were fixed in 10% neutral formalin solution and embedded in paraffin for histopathological staining. The samples were stained by hematoxylin and eosin (H&E) and then were examined for tubular damage by the pathologist. The kidney tissue damage was considered based on the presence of tubular dilation and simplification, tubular cell swelling and necrosis, tubular casts, and intraluminal cell debris with infiltration of inflammatory cells. Based on the intensity of tubular lesions, we scored from 1 to 4, while zero was assigned to the normal tissue without damage.

2.5. Statistical Analysis

The data are expressed as mean ± SEM. Statistical analysis of the serum levels of BUN, Cr, nitrite, and percentage of changes in body weight among the groups was performed using the one-way analysis of variance (ANOVA) followed by the least significant difference (LSD) test (post hoc multiple comparison). To compare the pathological damage score between the groups, Kruskal-Wallis and Mann-Whitney tests were used. The P value < 0.05 was considered statistically significant.

3. Results

From a total number of 64 animals, finally 45 rats survived up to the end of the experiment (Table 1).
Table 1

Mortality rate of animals in each group.

GroupGender N Day n
1234567
Sham M88
F88
L-NAMEM88
F88
CPM835
F853
CP + L-NAMEM844
F81223

N: total number of animals; n: number of animals survived up to the end of the experiment; CP: cisplatin; L-NAME: N-nitro L-arginine methyl ester; M: male; F: female.

3.1. Effect of CP on Body Weight

Weight loss induced by CP was expressed as the percentage (%) of body weight change. All CP-treated male and female animals significantly lost weight during the experiment compared with the sham or L-NAME-alone-treated groups. L-NAME accompanied with CP did not improve the weight loss induced by CP in both genders. The percentage of body weight change was not significantly different between the L-NAME-alone-treated and sham groups (Figure 1).
Figure 1

Blood urea nitrogen (BUN), creatinine (Cr), nitrite, percentage of weight change, and kidney tissue damage score (KTDS) in four male groups of sham, treated with L-NAME, CP, and L-NAME + CP. The star and cross symbols indicate significant difference from sham or CP groups, respectively.

3.2. Effect of CP on Serum Levels of BUN and Cr

The serum levels of BUN and Cr significantly increased in both male and female CP-alone-treated groups in comparison with the sham or L-NAME groups (P < 0.05). This was also the case in the L-NAME + CP groups for both genders. The combination of CP and L-NAME elevated the serum levels of BUN and Cr in male when compared with the corresponding CP-alone-treated group, while such finding was not observed for female (Figures 1 and 2).
Figure 2

Blood urea nitrogen (BUN), creatinine (Cr), nitrite, percentage of weight change, and kidney tissue damage score (KTDS) in four female groups of sham, treated with L-NAME, CP, and L-NAME + CP. The star and cross symbols indicate significant difference from sham or CP groups, respectively.

3.3. Effect of CP on Kidney Tissue Damage

The kidney damage induced by CP was evaluated and scored by two independent pathologists. The kidney tissue in the sham and L-NAME groups was considered as normal in two genders. The data showed that the kidney tissue damage induced by CP or by combination of CP and L-NAME significantly increased in male and female rats when compared with the sham or L-NAME-alone-treated groups (P < 0.05). However, coadministration of CP with L-NAME significantly enhanced kidney tissue damage in male but not female when compared with the CP-alone-treated groups (P < 0.05) (Figures 1 and 2). The images of kidney tissues in all experiment groups is demostraed in Figure 3. More kidney tissue damages were observed in groups treated with CP alone or combination of CP and L-NAME.
Figure 3

The images of kidney tissues (magnification ×100) in all experiment groups. More kidney tissue damages were observed in groups treated with CP alone or combination of CP and L-NAME.

4. Discussion

CP nephrotoxicity is very complex and includes several mechanisms such as accumulation of the drug in renal epithelial cells, attack of the drug to nuclear and mitochondrial DNA, and initiation of severe inflammatory response [11]. In the present study, we attempted to determine the role of L-NAME on CP-induced nephrotoxicity in male and female rats. CP induced significant decrease in body weight probably due to intestinal disturbance [12, 13]; however, the percentage of weight loss was not different between the genders, and L-NAME did not ameliorate the CP-induced weight loss. It is previously reported that pretreatment with L-NAME, as an NO inhibitor, markedly reduces the gastrointestinal toxicity induced by CP [14], and on the contrary, L-arginine, as an exogenous NO donor, increases the CP-induced weigh loss in female gender [15]. However, in this study, it seems that CP was responsible for such weight change. Continuous administration of CP increased serum levels of BUN and Cr in both genders at different levels. We obtained the same results in our previous study [3]. In addition, other investigations reported sex-related differences in toxicity induced by CP [15-18], but the mechanism of such sex difference is poorly understood. One parameter, which influences the BUN level, is the body water content. We did not measure the amount of food and water intake. However, CP-induced intestinal disturbance [12, 13] may disturb body water content and serum BUN level. Accompanying of L-NAME with CP aggravated renal dysfunction in male and female rats by increasing serum levels of BUN and Cr while these makers elevated more in male than female. Our results are in agreement with the results obtained in our previous study. Increasing the amounts of NO by the NO donor (L-arginine) exhibited different effects in male and female [15]. It is documented that L-arginine improves renal failure induced by CP in male [10, 15]. It seems that administration of L-NAME, as an NO inhibitor, aggravates CP-induced renal damage in male but not in female. The possible mechanism for such result may relate to gender dependency of the NO system. Our pathological investigation verified this effect, but, in contrast, Mansour et al. [19] reported that inhibition of all types of NOS with a nonselective inhibitor (L-NAME) or aminoguanidine reduced nephrotoxicity. It is reported that administration of L-NAME results in severe hypertension and causes kidney damage in rats [20]. NO production is also reported to be low in chronic kidney disease (CKD) patients, and NO deficiency may play a role in CKD progression [21, 22]. Chirino et al. [23] demonstrated that excessive NO derived from iNOS after CP administration contributes to the pathogenesis of CP-induced nephrotoxicity and NO has potential beneficial (preservation of renal blood flow and glomerular filtration) and detrimental (cytotoxicity caused by oxidative damage) effects [24]. NO inhibition by administration of nonselective inhibitors results in development of systemic and glomerular hypertension and glomerulosclerosis [20, 25, 26] and may aggravate the development of cyclosporine nephrotoxicity [27] and contrast-induced acute renal failure [28]. The inhibition of NO by L-NAME blocked all sources of NO produced from iNOS, nNOS, or eNOS, and therefore the nonbeneficial effect against CP-induced nephrotoxicity was expected. NO production by CP is also reported to be gender related [29]. We reported before that CP increases the serum total nitrite and nitrite levels in rats [30] and vitamin E could prevent the CP-induced nephrotoxicity via reduction of nitrite or total nitrite [29] gender dependently. It has also been shown that up to 70–90% of plasma nitrite is derived from eNOS activity in fasted subjects [31], while L-NAME inhibits all types of NO including eNOS. Therefore, no protection against CP-induced nephrotoxicity may occur. It is concluded that administration of L-NAME probably intensifies renal failure induced by CP in male gender. Of course more researches are needed to determine inhibition of which source of NO; iNOS, eNOS, or nNOS, is or is not efficient against CP-induced nephrotoxicity.
  29 in total

1.  Cisplatin-induced cytotoxicity in BSO-exposed renal proximal tubular epithelial cells: sex, age, and species.

Authors:  Yongke Lu; Akira Kawashima; Ikuo Horii; Laifu Zhong
Journal:  Ren Fail       Date:  2005       Impact factor: 2.606

2.  Cisplatin increases urinary sodium excretion in rats: gender-related differences.

Authors:  Donatas Stakisaitis; Giedre Dudeniene; Rimas Jonas Jankūnas; Grazina Grazeliene; Janina Didziapetriene; Birute Pundziene
Journal:  Medicina (Kaunas)       Date:  2010       Impact factor: 2.430

3.  Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage.

Authors:  C Baylis; B Mitruka; A Deng
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

4.  Total nitric oxide production is low in patients with chronic renal disease.

Authors:  R J Schmidt; C Baylis
Journal:  Kidney Int       Date:  2000-09       Impact factor: 10.612

5.  The role of angiotensin II receptor 1 (AT1) blockade in cisplatin-induced nephrotoxicity in rats: gender-related differences.

Authors:  Maryam Haghighi; Mehdi Nematbakhsh; Ardeshir Talebi; Hamid Nasri; Farzaneh Ashrafi; Kambiz Roshanaei; Fatemeh Eshraghi-Jazi; Zahra Pezeshki; Tahereh Safari
Journal:  Ren Fail       Date:  2012-07-11       Impact factor: 2.606

6.  p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice.

Authors:  Ganesan Ramesh; W Brian Reeves
Journal:  Am J Physiol Renal Physiol       Date:  2005-02-08

7.  Role of nitric oxide (EDRF) in radiocontrast acute renal failure in rats.

Authors:  D Schwartz; M Blum; G Peer; Y Wollman; A Maree; I Serban; I Grosskopf; S Cabili; Y Levo; A Iaina
Journal:  Am J Physiol       Date:  1994-09

8.  Vascular endothelial cells synthesize nitric oxide from L-arginine.

Authors:  R M Palmer; D S Ashton; S Moncada
Journal:  Nature       Date:  1988-06-16       Impact factor: 49.962

9.  Chronic L-NAME hypertension in rats and autoregulation of juxtamedullary preglomerular vessels.

Authors:  N Bouriquet; D Casellas
Journal:  Am J Physiol       Date:  1995-08

10.  Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone.

Authors:  Tatsuya Ohno; Shingo Kato; Masaru Wakatsuki; Shin-Ei Noda; Chiemi Murakami; Misako Nakamura; Hirohiko Tsujii
Journal:  Gynecol Oncol       Date:  2006-03-09       Impact factor: 5.482

View more
  12 in total

1.  Panax notoginseng saponins attenuates cisplatin-induced nephrotoxicity via inhibiting the mitochondrial pathway of apoptosis.

Authors:  Xinwen Liu; Zhenguang Huang; Xiaoqin Zou; Yufang Yang; Yue Qiu; Yan Wen
Journal:  Int J Clin Exp Pathol       Date:  2014-11-15

2.  Role of endothelin-1 antagonist; bosentan, against cisplatin-induced nephrotoxicity in male and female rats.

Authors:  Zahra Jokar; Mehdi Nematbakhsh; Maryam Moeini; Ardeshir Talebi
Journal:  Adv Biomed Res       Date:  2015-05-11

3.  Effect of enalapril in cisplatin-induced nephrotoxicity in rats; gender-related difference.

Authors:  Zohreh Zamani; Mehdi Nematbakhsh; Fatemeh Eshraghi-Jazi; Ardeshir Talebi; Sima Jilanchi; Mitra Navidi; Soheila Shirdavani; Farzaneh Ashrafi
Journal:  Adv Biomed Res       Date:  2016-01-29

4.  Cisplatin therapy and the problem of gender-related nephrotoxicity.

Authors:  Hamid Nasri
Journal:  J Nephropharmacol       Date:  2013-07-01

Review 5.  Renoprotective effects of antioxidants against cisplatin nephrotoxicity.

Authors:  Shabnam Hajian; Mahmoud Rafieian-Kopaei; Hamid Nasri
Journal:  J Nephropharmacol       Date:  2014-07-01

Review 6.  Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Fatemeh Eshraghi Jazi; Bahar Mazaheri; Maryam Moeini; Tahereh Safari; Fariba Azarkish; Fatemeh Moslemi; Maryam Maleki; Alireza Rezaei; Shadan Saberi; Aghdas Dehghani; Maryam Malek; Azam Mansouri; Marzieh Ghasemi; Farzaneh Zeinali; Zohreh Zamani; Mitra Navidi; Sima Jilanchi; Soheyla Shirdavani; Farzaneh Ashrafi
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

7.  Effect of infliximab against cisplatin-induced nephrotoxicity.

Authors:  Erkan Cure; Aynur Kirbas; Levent Tumkaya; Medine C Cure; Osman Z Sahin; Yildiray Kalkan; Suleyman Yuce; Durdu Altuner
Journal:  Saudi Med J       Date:  2014-09       Impact factor: 1.484

8.  Role of endothelin receptor antagonist; bosentan in cisplatin-induced nephrotoxicity in ovariectomized estradiol treated rats.

Authors:  Alieh Zahedi; Mehdi Nematbakhsh; Maryam Moeini; Ardeshir Talebi
Journal:  J Nephropathol       Date:  2015-10-01

9.  Role of S-methylisothiourea (SMT) in renal ischemia/reperfusion injury in rats.

Authors:  Fatemeh Kanani; Faezeh Fazelnia; Mohaddeseh Mojarradfard; Mehdi Nematbakhsh; Fatemeh Moslemi; Fatemeh Eshraghi-Jazi; Ardeshir Talebi
Journal:  J Renal Inj Prev       Date:  2016-02-28

10.  Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer.

Authors:  Nicole L K Pershing; Chi-Fu Jeffrey Yang; MengMeng Xu; Christopher M Counter
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.